Good morning, everyone. Welcome to the Jefferies Healthcare Conference 2026. For our next presentation, we have Marianne De Backer, CEO of Vir Biotechnology.
Hi. Good morning, everyone. Welcome to our presentation, Vir Biotechnology, and thank you, Jefferies, for the invitation. I will be making forward-looking statements, so I refer to risks and uncertainties as described in our SEC filings, and also to the disclaimer, which is in our corporate deck. We believe Vir Bio is poised for significant value creation. A number of reasons why. First of all, we have been steadily bringing in really execution-focused leadership. Recently, with a new CFO, Aziz Sawaf, and a new CMO, David Liu, we are really well-positioned to deliver on all of our catalysts. Second, we have delivered what I would describe as once-in-a-lifetime data from our ECLIPSE 1 delta pivotal trial, and I will be talking about that obviously more. Third, we have clinical validation now in our prostate cancer program, so in oncology.
We have declared proof of concept for our PSMA x CD3 masked T-cell engager. Again, more about that also later. Finally, we have growing validation for our PRO-XTEN masking technology platform, which is really a cornerstone of our future pipeline, and we have done a recent collaboration with Gilead on three PRO-XTEN masked T-cell engagers for solid tumors. Strong execution, meaningful validation, and multiple up-to-coming catalysts positioning us really well for value creation ahead. I will be talking first about our pivotal phase III results from ECLIPSE 1, our hepatitis delta trial, which, as I mentioned, is truly unbelievable results. First about the disease and a bit about the commercial opportunity. If you are co-infected with both the hepatitis B virus and the hepatitis delta virus, you really have very bad outlook.
More than 50% of the patients unfortunately die within a period of 10 years. They progress very swiftly to cirrhosis and liver failure. Five years is the average time that it takes, so the co-infection really accelerates the whole disease progression. Patients that are having the co-infection also progress to liver cancer three times faster than patients that are co-infected with hepatitis B alone. So it is the most severe form of viral hepatitis, and the estimated number of patients in U.S. are 61,000, a little bit less than double in Europe, and in the world, about 7 million people. Unfortunately, it is a disease that has been largely underdiagnosed, and there is a couple of reasons for that. First of all, for a long period of time, actually until May of this year, there was no regimen available for patients in the U.S.
It is only recently that it really makes sense to get patients tested, because now they can be treated. There is a couple of levers, though, that are really pointing very positively to increased diagnosis. The first one is at a recent liver meeting, AASLD, there was a group of delta experts that put out a paper, the EXPO paper, that was suggesting that every patient that tests positive for hepatitis B should be reflex tested for hepatitis delta. If that happens, if every single patient that gets diagnosed for hepatitis B gets tested for delta, that would significantly increase, obviously, the testing rate and increase the diagnosis rate. We have some good numbers from Europe.
There was a couple of papers on where they analyzed in Spain the effects of reflex testing, where testing went up from 8% to 93% of the B patients, and they also saw three- to five-fold higher diagnosis. That is a very important lever. Secondly, about a year ago, I couldn't say that, but now the testing availability in major labs like LabCorp, Quest, is available. Roche has brought out an RNA test. Everything is there now.
There is no hurdle anymore to get patients tested. Technologically, it is an antibody test, it is an RNA test, it is not complicated, and it is available. Thirdly, you know that GSK has recently announced approval of their bepi treatment, which is a functional cure for a subset of B patients, and there is also more delta regimens coming, such as ours. That is also another impetus for more testing for hepatitis B.
The larger the funnel of patients that get tested for hepatitis B, the more patients with delta we will be able to identify. We believe this is an over billion-dollar opportunity, just because of the already identified and diagnosed patients in the U.S., and because this is a rare disease and demands orphan disease pricing. Now, about our results. Again, one in a lifetime, these results were significantly better than we had hoped for. Our ECLIPSE 1 trial showed that after 48 weeks of treating patients with a monthly regimen of elebsiran and tobevibart, we could get nearly 80% of the patients to undetectable virus. With an RT-PCR from the blood of patients, you could no longer detect the virus. Really stunning results.
We also did some further analysis, and you see that here on the right-hand side in our phase II trial, where we followed patients for a longer period of time. We had 28 patients that stayed on treatment for 96 weeks, and basically all of them, 100%, got to undetectable virus. Then we did a sub-analysis of a number of patients that were really well controlled for over 96 weeks, so undetectable. We gave them the option to come off treatment and to explore whether a cure would be possible, a finite treatment. We saw that 10 out of the 10 patients that elected to do that showed sustained viral responses, varying between 12 and 48 weeks. Early data, but sort of the early signs that we could have a curative regimen for delta. Very promising results.
We are going to get additional results from our ECLIPSE 2 and 3 trial in the first quarter of next year, then are planning to file mid-next year. A little bit more about our full registrational program. I talked about ECLIPSE 1. ECLIPSE 2 is going to be looking at Hepcludex failures, and really look at switching those patients over to our regimen. ECLIPSE 3 is a head-to-head trial with Hepcludex, really very important for payers, especially in Europe. Taken together, that will be a very comprehensive package. Now, about our regimen. As is typical in virology, and also what we have seen, we have compared our antibody alone with our antibody combined with an siRNA. As in typical in virology, what you typically see is that when you combine several mechanism of actions, you get the deepest and most durable results.
That's also what we see here. We have an siRNA that basically dices up all the transcripts from hepatitis B and prevents HBs surface antigen from forming. We have an antibody that neutralizes the delta and the B virions and avoids that these viruses enter into the liver cells, into the hepatocytes. So a powerful combination, a two-pronged approach, attacking the virus in a number of different ways. It's a monthly regimen, as I mentioned, so two injections once a month. It will be possible at launch for patients to elect to either do at-home administration themselves or go to a physician's office once a month and get their injections. The ECLIPSE 1 design is very straightforward, 2:1 randomized trial where patients either directly get on elebsiran and tobevibart for 48 weeks, or they get a 12-week deferred treatment.
The deferred treatment is no treatment, so it's really as if you have a placebo-controlled trial. These were the results. On the left-hand side, you see the viral RNA. The orange bar is sort of showing you what is typically called virologic response. The bar is a little bit lower. You only need to see a two-log decline of RNA. You can see that with that, we get to nearly all the patients to that level in a period of four weeks' time. Then gradually, all the patients get a virological response. More importantly is the blue line. Do you really get rid of the virus in the patients? You show here this gradual increase over time where you get more and more patients to undetectable.
Eventually, as mentioned, at 48 weeks, we got nearly 80% of the patients to undetectable RNA. On the right-hand side is ALT normalization, and also there you see this gradual increase in ALT normalization, where across sort of all the regimens that you look at 48 weeks, you typically end up somewhere between 50% and 60% in the broad population of ALT normalization. Importantly, 55% of the patients in our trial were cirrhotics. That is very important because what physicians typically have is that patients are already advanced to being cirrhotic by the time they see them. We were able to show very great results in this subset of more advanced patients, where 85% actually got to undetectable viral levels. So, really important that our regimen works across non-cirrhotic and cirrhotic patients. A brief moment on hepatitis B surface antigen. Why does it matter?
HB surface antigen is obviously, as the name says, a protein that is on the surface of the B virus, but it is because the delta virus is a defective virus, it is necessary for delta. Delta needs it to form its viral envelope and to enter into hepatocytes. What we here do with siRNA component of the regimen is we dice up all the transcripts that are being formed continuously of HBs surface antigen. You see here the levels of S surface antigen going down quite dramatically, and it is this combination, again, of an siRNA and an antibody that allows you to show those very impressive viral efficacy results. The regimen was well tolerated, so everyone, there was no drug interruptions, there was no discontinuations. The majority of adverse events were mild to moderate in severity. No serious adverse events.
The most seen was flu-like symptoms in a subset of patients, and this was mostly at the first very dose that patients ever got. The very first time they had the two injections, they had these, subset of patients had these mild to moderate flu-like symptoms, which were transient and resolved after 24 to 48 hours. In the next doses, these symptoms were not recurring. This is really something at the first dose when really the regimen and the immune system gets activated. Very briefly about our phase II finite treatment results.
As mentioned, given the tremendous viral efficacy we see here for this chronic treatment, we did ask ourselves, because delta is an RNA virus, very similar to hepatitis C virus, is it also possible to potentially have a finite treatment, treat patient for a finite amount of time, and then see if they are actually cured and remain controlled? We explored that in a small subset of patients. As I mentioned, patients who were 96 weeks at undetectable levels could elect to come off treatment, and 10 patients elected to do so. Seven of them were actually cirrhotics. Then we looked at what happened to their RNA levels and their ALT levels. You can see that here on the left-hand side of the slide, every single patient remained controlled and undetectable.
Varied time frames, some 12 weeks, some 48 weeks, but that is just because of the time the data cut was made. All these patients are continuously being followed. On the right-hand side, you can also see these patients were all ALT normalized and stayed ALT normalized over time. Very early data set, but sort of the first signal that a curative regimen might be possible here for hepatitis delta. After these great results on delta, I do want to switch gears to our oncology pipeline. One of the most defining features that we have is a platform called PRO-XTEN.
You all know that there's a lot of T-cell engagers that are already on the market, mostly actually for liquid tumors, and they have this incredible potential of activating in vivo the T-cells that are already there to fight cancer, to fight your tumor. Unfortunately, with solid tumors, it has been very challenging because there is a lot of toxicity, there's CRS, there's ICANS, and a lot of the development and the progression of T-cell engagers in solid tumors has been held back by that toxicity profile. You have to give very high levels of steroids and anti-IL-6 and whatever in order for patients to be able to tolerate the T-cell engagers. What we have is a masking technology. You see that gray spaghetti around the T-cell engager.
What it basically does is that it forms this hydrophilic polypeptide around your T-cell engager, so when the drug is given, it circulates in your blood and nothing happens. But when you enter the tumor microenvironment, there's going to be proteases there that are going to cleave that mask off. This entire gray mask is going to fall off, and only then the T-cell engager is going to get activated. The tumor binding domain is going to bind to tumor cells. The CD3 binding domain is going to bind to T-cells. They're going to be brought together, and the T-cells are going to be killing the tumor. This is a very unique technology. It's a plug-and-play technology, which is really great. For every T-cell engager, we don't need to develop a new mask. We can take exactly the same mask on all of our molecules.
These are our three programs in the clinic that use this technology. One is VIR-5500. This is in a collaboration with Astellas, being developed for prostate cancer. We, just two and a half weeks ago or so, received Fast Track designation for late-line mCRPC, and we are developing this drug in a number of different cohorts and are expecting to start pivotal trials next year. Our second drug is a HER2 CD3 masked T-cell engager, which is a basket trial, looking at efficacy across a number of different tumor types. We are looking now to look at data in more homogeneous populations as well, and dose escalation is ongoing in the phase I. Then third, we have VIR-5525, which is an EGFR CD3 masked T-cell engager, which is also in phase I and dose escalation, both as monotherapy and in combination with the camrelizumab.
We are going to be hosting a research event in the first quarter of next year, which also will lift the veil on a number of preclinical programs that we have ongoing, some of them using the PRO-XTEN technology. Again, we entered into a Gilead deal on three PRO-XTEN masked T-cell engagers for solid tumors just a couple of weeks ago. Very briefly on our PSMA-targeted T-cell engager, again, this is a collaboration with Astellas. We have shown data back in February showing that we could really achieve a very great therapeutic index with grade PSA 50s to 99 percentages. You see them here. PSA 99 of almost one in three patients, 29%, 45% ORR, and with a very nice safety profile, which is really what you want to show here.
Most of our CRS was grade 1 or grade 2, 50% grade 1, which is significantly differentiating versus other unmasked T-cell engagers. This was just a case example, a patient example that I showed back in February as well from a 63-year-old patient that had severe liver mets, 14 lesions in the liver, was treated with our regimen, and then nine weeks later, you could see the results here on PSMA PET. That is sort of the power of really activating a patient's own immune system to fight the cancer. That's really what you are doing here.
We were very glad to see this, and we are continuing to develop this drug in a number of different cohorts, both for late-line mCRPC and early-line mCRPC, both as a monotherapy and a combination with enzalutamide and docetaxel for early-line mCRPC, and a combination with darolutamide and abiraterone for hormone-sensitive prostate cancer. That is all ongoing, and we expect clinical trials, pivotal studies to start next year. More to come on that program. In conclusion, we have a really very promising program for hepatitis delta with additional catalysts coming in the first quarter, and then, of course, filing mid-next year. For our oncology pipeline, we are going to start pivotal trials next year, and of course, we'll be reporting on that design in the course of 2027. We have two additional clinical trials ongoing for HER2 and EGFR masked T-cell engagers in phase I.
Finally, we have a discovery engine which is really powerful and which we will be sharing more information on in the first quarter of next year, but great validation through this collaboration on three T-cell engagers with Gilead. We are using collaborations quite strategically, as you might have seen, and we will continue to do so. We have a platform in oncology that is so powerful that there is much more that we can do than we can ever bring forward on our own to the clinic and to market, so there will be an opportunity for further business development.
Finally, we are very well financed, so we had $901 million of cash at the end of the first quarter, and we have a cash runway into 2029, and this includes actually $90 million from an upfront payment from Gilead in the collaboration and also proceeds from our equity raise last week. Thank you for your attention. I'll be happy to take questions.